Literature DB >> 24828321

HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain.

L Gulácsi1, M Péntek.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24828321     DOI： 10.1007/s10198-014-0608-2

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  21 in total

1.  Costs of dementia in Hungary.

Authors:  K Érsek; T Kovács; A Wimo; K Kárpati; V Brodszky; M Péntek; L Jönsson; A Gustavsson; D McDaid; P A Kenigsberg; H Valtonen; L Gulácsi
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Major challenges ahead for Hungarian healthcare.

Authors:  Péter Gaál; Szabolcs Szigeti; Dimitra Panteli; Matthew Gaskins; Ewout van Ginneken
Journal:  BMJ       Date:  2011-12-07

3.  Effect of surgical delay on early mortality in patients with femoral neck fracture.

Authors:  Andor Sebestyén; Imre Boncz; János Sándor; József Nyárády
Journal:  Int Orthop       Date:  2007-02-24       Impact factor: 3.075

4.  The effect of an organized, nationwide breast cancer screening programme on non-organized mammography activities.

Authors:  Imre Boncz; Andor Sebestyén; István Pintér; István Battyány; István Ember
Journal:  J Med Screen       Date:  2008       Impact factor: 2.136

5.  User fees for public health care services in Hungary: expectations, experience, and acceptability from the perspectives of different stakeholders.

Authors:  Petra Baji; Milena Pavlova; László Gulácsi; Wim Groot
Journal:  Health Policy       Date:  2011-05-04       Impact factor: 2.980

6.  Exploring health care reform in a changing Europe: lessons from Greece.

Authors:  Antonis A Kousoulis; Konstantina-Eleni Angelopoulou; Christos Lionis
Journal:  Eur J Gen Pract       Date:  2013-04-12       Impact factor: 1.904

7.  Financial crisis, austerity, and health in Europe.

Authors:  Marina Karanikolos; Philipa Mladovsky; Jonathan Cylus; Sarah Thomson; Sanjay Basu; David Stuckler; Johan P Mackenbach; Martin McKee
Journal:  Lancet       Date:  2013-03-27       Impact factor: 79.321

8.  Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries.

Authors:  Z Kaló; K Landa; T Doležal; Z Vokó
Journal:  Eur J Cancer Care (Engl)       Date:  2012-04-18       Impact factor: 2.520

9.  Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis.

Authors:  András Inotai; Bernadette Rojkovich; Angéla Fülöp; Emese Jászay; Tamás Agh; Agnes Mészáros
Journal:  Rheumatol Int       Date:  2011-01-18       Impact factor: 2.631

10.  Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

Authors:  Polina Putrik; Sofia Ramiro; Tore K Kvien; Tuulikki Sokka; Till Uhlig; Annelies Boonen
Journal:  Ann Rheum Dis       Date:  2013-08-12       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.